Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.6499 +0.0299 (+4.82%)
Streaming Delayed Price Updated: 1:59 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated as Treatment for Multiple Conditions
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
Via CannabisNewsWire
News headline image
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-... 
Via Benzinga
Lexaria (NASDAQ: LEXX) Technology Shows Promise in Improving Performance of ED Drugs
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs
Via Investor Brand Network
News headline image
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating... 
Via Benzinga
Lexaria (NASDAQ: LEXX) CEO Summarizes 2021 Milestones in Letter to Shareholders
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders
Via Investor Brand Network
News headline image
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study ↗
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
Via Investor Brand Network
News headline image
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the... 
Via Benzinga
Lexaria (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Tech on EDGE Podcast
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast
Via Investor Brand Network
Lexaria (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
Via Investor Brand Network
News headline image
Lexaria Provides Annual Letter From the CEO
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
Via CannabisNewsWire
News headline image
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2 ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Comments on Study Examining Cannabinoids and SARS-CoV-2
Via Investor Brand Network
Topics Cannabis
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.